A5102449229- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Intraoperative Neuromonitoring and Anesthetic Effects
- Intraocular Surgery and Lenses
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Macular Surgery
- Intracranial Aneurysms: Treatment and Complications
- Cerebral Venous Sinus Thrombosis
- Retinal Development and Disorders
- Ophthalmology and Eye Disorders
- Facial Trauma and Fracture Management
- Traumatic Brain Injury and Neurovascular Disturbances
- Drug-Induced Ocular Toxicity
- Vascular Malformations Diagnosis and Treatment
- Traumatic Ocular and Foreign Body Injuries
- Cerebrovascular and Carotid Artery Diseases
- Retinopathy of Prematurity Studies
- Neurosurgical Procedures and Complications
- Ocular Oncology and Treatments
- Ocular Infections and Treatments
- Spinal Fractures and Fixation Techniques
- Drug-Induced Adverse Reactions
- Pharmacological Effects of Natural Compounds
Elman Retina Group
2014-2024
University of Baltimore
2021
National Eye Institute
2016
National Institutes of Health
2016
Johns Hopkins University
1986-2013
Johns Hopkins Medicine
1989-2013
Jaeb Center for Health Research
2008-2010
Pain Management Center of Paducah
2010
Research Medical Center
2010
University of Florida Health Science Center
2010
The relative efficacy and safety of intravitreous aflibercept, bevacizumab, ranibizumab in the treatment diabetic macular edema are unknown.
Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy. However, PRP can damage retina, resulting in peripheral vision or worsening macular edema (DME).To evaluate noninferiority of intravitreous ranibizumab compared with acuity outcomes patients retinopathy.Randomized clinical trial conducted at 55 US sites among 305 adults retinopathy enrolled between February and December 2012 (mean age, 52 years; 44% female; 52%...
<h3>Importance</h3> The Age-Related Eye Disease Study (AREDS) formulation for the treatment of age-related macular degeneration (AMD) contains vitamin C, E, beta carotene, and zinc with copper. 2 (AREDS2) assessed value substituting lutein/zeaxanthin in AREDS because demonstrated risk lung cancer from carotene smokers former lutein zeaxanthin are important components retina. <h3>Objective</h3> To further examine effect supplementation on progression to late AMD. <h3>Design, Setting,...
Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed.To evaluate efficacy and safety of 0.5-mg intravitreous ranibizumab vs panretinal photocoagulation (PRP) over 5 years PDR.Diabetic Retinopathy Clinical Research Network multicenter randomized clinical trial evaluated 394 study PDR enrolled February December 2012. Analysis began in January 2018.Eyes were randomly assigned to receive (n = 191)...
After the Age-Related Eye Disease Study 2 (AREDS2) study, beta carotene component was replaced by lutein/zeaxanthin for development of revised AREDS supplement. However, it is unknown if increased risk lung cancer observed in those assigned persists beyond conclusion AREDS2 trial and there a benefit adding to original supplement that can be with long-term follow-up.To assess 10-year developing late age-related macular degeneration (AMD).This multicenter epidemiologic follow-up study clinical...
Anterior ischemic optic neuropathy (AION) is caused by sudden loss of vascular supply to retinal ganglion cell (RGC) axons in the anterior portion nerve and a major cause dysfunction. There has been no easily obtainable animal model this disorder. The current study was conducted design novel rodent AION (rAION), enable more detailed disease.A photoembolic stroke developed that directly analogous human AION. Using histologic, electrophysiological, molecular- biological methods, early changes...
In this cross-sectional study, the authors evaluated 197 patients diagnosed with central retinal vein occlusion (CRVO) at Wilmer Ophthalmological Institute between 1980 and 1985 to determine risk of systemic disease mortality. Complete follow-up information for mortality was obtained in 191 (97%). National Health Interview Survey (NHIS) cataract formed two comparison groups. The prevalence hypertension significantly elevated CRVO cases when compared both groups (P less than 0.03, 0.005)....
• One hundred three patients with neovascular maculopathy and relatively recent vision loss were surveyed to determine the most frequent symptoms assess reliability of Amsler grid in helping detect early symptoms. Blurred distortion, often near vision, first reported by patients. Of 49 who said that they observing on a regular basis, only five indicated abnormality was visual symptom. However, all but did notice an during office examination, suggesting noncompliance as probable explanation...
<h3>Objective</h3> To compare the effects of single-sitting vs 4-sitting panretinal photocoagulation (PRP) on macular edema in subjects with severe nonproliferative or early proliferative diabetic retinopathy relatively good visual acuity and no mild center-involved edema. <h3>Methods</h3> Subjects were treated 1 sitting 4 sittings PRP a nonrandomized, prospective, multicentered clinical trial. <h3>Main Outcome Measure</h3> Central subfield thickness optical coherence tomography (OCT)....
Electroretinograms (ERGs) were measured in 15 patients with central retinal vein occlusion (CRVO). Seven of the had neovascularization iris (NVI) at time testing, and two developed NVI within one month testing; six did not have or any other form (NV) no longer considered to be risk for NV from their present occlusion. The ERGs recorded as a function stimulus intensity 30-Hz flickering stimulus. A Naka-Rushton-type was fit b-wave amplitudes, intensity, evaluate changes ERG amplitude...
To evaluate the effect of a topical, nonsteroidal antiinflammatory drug, nepafenac 0.1%, in eyes with noncentral diabetic macular edema.
Comparisons of the relative effect 3 anti-vascular endothelial growth factor agents to treat diabetic macular edema warrant further assessment.